Ascelia Pharma: FDA feedback confirms that Orviglance is on track for NDA submisison - Redeye
FDA's final minutes confirm that Orviglance is on track for NDA submission by mid-2025. The final minutes’ feedback is an essential step in the pre-submission process, and both the timetable and the format are de-risked as a result.
ANNONS
FDA's final minutes confirm that Orviglance is on track for NDA submission by mid-2025. The final minutes’ feedback is an essential step in the pre-submission process, and both the timetable and the format are de-risked as a result.